Adult Influenza Vaccine: Safety and Clinical Effectiveness
This paper examines the influenza vaccine as a preventive measure against a contagious respiratory illness that affects millions of people globally each year. It reviews the clinical effectiveness of the vaccine across different age groups, noting that efficacy in healthy adults ranges from 40% to 60% and tends to be lower in older adults due to immunosenescence. The paper also addresses safety concerns, including mild side effects, the rare risk of Guillain-Barré Syndrome, and egg-allergy considerations. Additionally, it discusses specialized high-dose and adjuvanted formulations developed for elderly populations, the role of vaccination in chronic disease management, and the importance of public health communication in overcoming vaccine hesitancy.
- Introduction: Overview of influenza and vaccine's preventive role
- Clinical Effectiveness of the Influenza Vaccine: Efficacy rates, herd immunity, and disease burden reduction
- Safety Concerns of the Influenza Vaccine: Adverse events, GBS risk, egg allergies, and surveillance
- Promoting Health Across the Lifespan: High-dose vaccines and chronic disease management in elderly
- Conclusion: Vaccine hesitancy, communication, and lifelong immunization culture
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper balances both efficacy and safety dimensions of the influenza vaccine, giving readers a well-rounded view rather than a one-sided advocacy piece.
- It distinguishes between population subgroups — healthy adults, older adults, and those with chronic conditions — demonstrating nuanced thinking about how vaccine outcomes vary by demographic.
- Claims are consistently tied to peer-reviewed citations, lending academic credibility to each argument made throughout the discussion.
Key academic technique demonstrated
The paper consistently uses hedged language ("is believed to," "is said to," "the evidence suggests") to accurately represent the probabilistic and consensus-based nature of public health research. This technique shows awareness that vaccine effectiveness data comes from population-level studies rather than guaranteed individual outcomes — an important distinction in health sciences writing.
Structure breakdown
The paper follows a clear four-part structure: an introduction establishing the clinical significance of influenza vaccination; a section on clinical effectiveness covering efficacy rates, herd immunity, and disease burden reduction; a section on safety covering adverse events, egg allergies, and surveillance systems; and a section on lifespan health promotion focusing on high-dose vaccines and chronic disease management. The conclusion ties these threads together with a public health communication perspective on vaccine hesitancy.
Introduction
Influenza is a contagious respiratory illness caused by influenza viruses that affects millions of people globally every year and can cause morbidity and mortality among older adults and those with underlying health conditions (Javanian et al., 2021). Vaccination is considered by many in the medical community to be the best preventive measure against influenza. This discussion focuses on the influenza vaccine and examines its safety concerns and clinical effectiveness in promoting health across the lifespan, especially in adults and older populations.
Clinical Effectiveness of the Influenza Vaccine
The clinical effectiveness of the influenza vaccine varies with age and health status (Lee et al., 2021). In healthy adults, the vaccine's efficacy can range from 40% to 60%, depending on the match between the vaccine strains and the circulating strains of the virus. For older adults, efficacy tends to be lower due to immunosenescence, which is a decline in immune function that occurs with age (Lee et al., 2021). However, the vaccine can still be viewed by medical providers as beneficial for the elderly because of evidence that it significantly reduces the severity of illness, the need for hospitalization, and the risk of complications such as pneumonia and the worsening of already existing chronic conditions (Tenforde et al., 2021).
The widespread use of the influenza vaccine is also believed to contribute to herd immunity, which is said to reduce the overall circulation of the virus in the community (Marlowe et al., 2022). This effect protects vulnerable populations, including infants who are too young to be vaccinated and people with compromised immune systems. Annual vaccination is recommended by most medical providers as an effective measure against the predominant strains of influenza virus, which are believed to change each year — which is why updated vaccines are recommended for continued protection (Marlowe et al., 2022).
Influenza vaccination is also said to reduce the incidence of flu-related medical visits, hospitalizations, and deaths. Researchers have argued that vaccination can prevent millions of flu cases and thousands of hospitalizations and deaths each year. This reduction in disease burden translates to decreased healthcare costs and less strain on healthcare resources, particularly during peak flu seasons (Lee et al., 2021).
Safety Concerns of the Influenza Vaccine
The influenza vaccine has a well-established safety profile (Tenforde et al., 2021). Most side effects are considered mild and transient, such as soreness at the injection site, fever, and muscle aches; these side effects typically resolve within a few days and do not pose serious health risks. However, serious adverse events following influenza vaccination can and do occur. One such event is Guillain-Barré Syndrome (GBS), a condition in which the immune system attacks the nerves, causing muscle weakness and paralysis (Koike & Katsuno, 2021). The risk of GBS after vaccination is estimated at approximately one to two cases per million vaccinations, and the risk of developing GBS after natural influenza infection is thought to be higher than after vaccination.
Most influenza vaccines are produced using egg-based manufacturing processes, which has raised concerns for people with egg allergies. However, studies have shown that the risk of an allergic reaction to the vaccine is very low, even in those with severe egg allergies (Lee et al., 2021). For those concerned about this issue, egg-free vaccine options are available and are recommended by medical providers.
Vaccine safety is continuously monitored through systems such as the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD), which collect data on adverse events following vaccination and are helpful for identifying potential safety concerns. This surveillance framework ensures that any safety signals can be quickly identified and addressed.
Conclusion
Supporting a culture of lifelong immunization is an important public health goal, which is why public health campaigns and healthcare providers place significant emphasis on educating people about the importance of getting their annual influenza vaccine. This is particularly important for older adults, who may have concerns about vaccine safety and efficacy. Clear communication about the benefits and risks of vaccination can help improve uptake rates. Vaccine hesitancy — potentially driven by distrust of the medical community, especially in the wake of COVID-19 — remains a barrier to broader coverage; however, it is unclear whether the elderly population shares the same degree of vaccine skepticism as younger people may have.
References
Javanian, M., Barary, M., Ghebrehewet, S., Koppolu, V., Vasigala, V., & Ebrahimpour, S. (2021). A brief review of influenza virus infection. Journal of Medical Virology, 93(8), 4638–4646.
Koike, H., & Katsuno, M. (2021). Emerging infectious diseases, vaccines and Guillain-Barré syndrome. Clinical and Experimental Neuroimmunology, 12(3), 165–170.
Lee, J. K., Lam, G. K., Shin, T., Samson, S. I., Greenberg, D. P., & Chit, A. (2021). Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis. Vaccine, 39, A24–A35.
Marlowe, E., Pranikoff, S., Borsheim, B., Salafian, K., Halvorson, E. E., & Kram, D. E. (2022). Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates. Vaccine, 40(46), 6625–6630.
Tenforde, M. W., Chung, J., Smith, E. R., Talbot, H. K., Trabue, C. H., Zimmerman, R. K., ... & Patel, M. M. (2021). Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015–2018. Clinical Infectious Diseases, 73(3), 386–392.
Always verify citation format against your institution’s current style guide requirements.